p53 tumor suppressor fragment
(Synonyms: H2N-Lys-Tyr-Met-Cys-Asn-Ser-Ser-Cys-Met-OH ) 目录号 : GP10036
Regulates cell cycle
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
p53 tumor suppressor fragment (232-240),(C41H67N11O14S4), a peptide with the sequence H2N-Lys-Tyr-Met-Cys-Asn-Ser-Ser-Cys-Met-OH, MW= 1066.3. p53 (also known as protein 53 or tumor protein 53), is a tumor suppressor protein that in humans is encoded by the TP53 gene1. p53 is crucial in multicellular organisms, where it regulates the cell cycle and, thus, functions as a tumor suppressor that is involved in preventing cancer. As such, p53 has been described as "the guardian of the genome" because of its role in conserving stability by preventing genome mutation2. p53 has many mechanisms of anticancer function, and plays a role in apoptosis, genomic stability, and inhibition of angiogenesis. In its anti-cancer role, p53 works through several mechanisms:It can activate DNA repair proteins when DNA has sustained damage. It can induce growth arrest by holding the cell cycle at the G1/S regulation point on DNA damage recognition.It can initiate apoptosis, the programmed cell death, if DNA damage proves to be irreparable3.
References:
1. Cho, Y.; Gorina, S.; Jeffrey, P. D.; Pavletich, N. P. (1994). "Crystalstructure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations". Science 265 (5170): 346-355.
2. Read, A. P.; Strachan, T.. Human molecular genetics 2. New York: Wiley; 1999. ISBN 0-471-33061-2. Chapter 18: Cancer Genetics.
3. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene. 1999;18(53):7621-36.
| Cas No. | SDF | ||
| 别名 | H2N-Lys-Tyr-Met-Cys-Asn-Ser-Ser-Cys-Met-OH | ||
| Canonical SMILES | NC(CCCCN)C(NC(CC1=CC=C(O)C=C1)C(NC(CCSC)C(NC(CS)C(NC(CC(N)=O)C(NC(CO)C(NC(CO)C(NC(CS)C(NC(CCSC)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O | ||
| 分子式 | C41H67N11O14S4 | 分子量 | 1066.3 |
| 溶解度 | ≥ 53.3mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9378 mL | 4.6891 mL | 9.3782 mL |
| 5 mM | 0.1876 mL | 0.9378 mL | 1.8756 mL |
| 10 mM | 0.0938 mL | 0.4689 mL | 0.9378 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet